Literature DB >> 25642314

Mantle cell lymphoma: observation to transplantation.

Babak Rajabi1, John W Sweetenham2.   

Abstract

Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

Entities:  

Keywords:  chemo-immunotherapy; ibrutinib; mantle cell lymphoma; transplantation

Year:  2015        PMID: 25642314      PMCID: PMC4298490          DOI: 10.1177/2040620714561579

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN: 2040-6207


  77 in total

1.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

Authors:  Lina Nygren; Stefanie Baumgartner Wennerholm; Monika Klimkowska; Birger Christensson; Eva Kimby; Birgitta Sander
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

2.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Authors:  John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

4.  The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Authors:  Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

5.  Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.

Authors:  Stephen E Spurgeon; Talia Pindyck; Craig Okada; Yiyi Chen; Zunqiu Chen; Elana Mater; Kamal Abbi; Elliot M Epner
Journal:  Leuk Lymphoma       Date:  2011-05-31

6.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  Richard Delarue; Corinne Haioun; Vincent Ribrag; Pauline Brice; Alain Delmer; Herve Tilly; Gilles Salles; Achiel Van Hoof; Olivier Casasnovas; Nicole Brousse; Francois Lefrere; Olivier Hermine
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

7.  Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

Authors:  Ann S LaCasce; Jonathan L Vandergrift; Maria A Rodriguez; Gregory A Abel; Allison L Crosby; Myron S Czuczman; Auayporn P Nademanee; Douglas W Blayney; Leo I Gordon; Michael Millenson; Ann Vanderplas; Eva M Lepisto; Andrew D Zelenetz; Joyce Niland; Jonathan W Friedberg
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

8.  Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Authors:  Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113

9.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Georg Hess; Raoul Herbrecht; Jorge Romaguera; Gregor Verhoef; Michael Crump; Christian Gisselbrecht; Anna Laurell; Fritz Offner; Andrew Strahs; Anna Berkenblit; Orysia Hanushevsky; Jill Clancy; Becker Hewes; Laurence Moore; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more
  2 in total

Review 1.  Bortezomib for the treatment of mantle cell lymphoma: an update.

Authors:  Bryan Hambley; Paolo F Caimi; Basem M William
Journal:  Ther Adv Hematol       Date:  2016-05-21

2.  Exosome complex genes mediate RNA degradation and predict survival in mantle cell lymphoma.

Authors:  Weilong Zhang; Junyong Zhu; Xue He; Xiaoni Liu; Jinhang Li; Wei Li; Ping Yang; Jing Wang; Kai Hu; Xiuru Zhang; Xiru Li; Hongmei Jing
Journal:  Oncol Lett       Date:  2019-09-11       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.